Skin boosters vs dermal fillers: dermal fillers are typically firmer, more cross-linked hyaluronic acid (HA) gels used to restore volume and contour, while skin boosters are softer injectables placed in or near the dermis to improve skin quality such as hydration and texture. They are complementary tools, not substitutes, and results vary by product and patient.
Key Takeaways
- Fillers target volume and structure; skin boosters target dermal quality (hydration, texture, radiance).
- Cross-linking, HA concentration and cohesivity drive how a gel behaves in tissue and how long it lasts.
- “Skin booster” is a broad, loosely defined term that also covers polynucleotides, PDRN, PLLA and others.
- Published evidence for injectable HA skin quality is encouraging but limited, with small and heterogeneous studies.
- Distributors should confirm intended use, documentation and cold-chain handling product by product.
What Is the Difference Between Skin Boosters and Dermal Fillers?
The core difference is intent. Fillers are chosen to add support and shape; skin boosters are chosen to improve the quality of the skin itself.
A 2022 review in Facial Plastic Surgery by de la Guardia and colleagues explains that cross-linked HA forms a gel that resists enzymatic breakdown, so it lasts longer, and that more cross-linking makes a gel firmer, more elastic and less prone to swelling. Less cross-linked gels are softer and deform more easily, which suits superficial placement. Note that several authors of that paper are employees of a filler manufacturer.
The term "skin booster" itself has no single agreed definition. A 2024 narrative review proposed a broad working definition (substances injected or applied to penetrate the dermis that influence rejuvenation). That article was later retracted, so we cite it only to illustrate how loosely the term is used and rely on other sources for evidence.
| Feature | Dermal filler | Skin booster |
|---|---|---|
| Primary goal | Volume, contour, support | Hydration, texture, dermal quality |
| Typical HA design | Cross-linked, firmer gel | Non-cross-linked or lightly cross-linked, softer gel |
| Typical placement | Per product labeling, often deeper | Superficial, in or near the dermis |
| Treatment planning | Often fewer, targeted sessions | Often a series of sessions, per the clinician's protocol |
| Other materials in the category | Calcium hydroxylapatite, PLLA (in some products) | Polynucleotides, PDRN, PLLA, PCL-based and other products |
How Do Cross-Linking and Rheology Change Clinical Behavior?
Cross-linking, HA concentration and cohesivity together determine how a gel spreads, lifts and persists. No single number tells the whole story.
G′ (elastic modulus) is the most common descriptor of firmness and is traditionally linked to lift capacity, but de la Guardia et al. note the relationship is not always linear across different manufacturing technologies. Cohesivity describes how well a gel holds together under compression; low-cohesivity gels mold and spread easily, while high-cohesivity gels keep their shape. The authors also point out that no standardized cohesivity assay exists, so cross-brand comparisons should be made carefully.
For a deeper look, see our explainer on cross-linked vs non-cross-linked HA skin boosters.
What Does Clinical Evidence Say About Skin Boosters?
Evidence suggests injectable HA can improve hydration and radiance, but the studies are few, small and varied, so conclusions should be modest.
A 2025 systematic review and meta-analysis in the Journal of Cosmetic Dermatology (Zhou and Yu) included 12 studies, of which 6 were pooled. Versus controls, HA injection showed improved hydration (SMD 1.34, 95% CI 0.14–2.54, I² = 98%) and radiance (SMD 0.51, 95% CI 0.22–0.80), but no significant effect on elasticity (SMD 0.25, 95% CI −0.20–0.70) or melanin index. When one outlier study was removed, the hydration result lost statistical significance. The authors cite few eligible studies, high heterogeneity and product variability as limitations.
A 2023 systematic review in Clinical, Cosmetic and Investigational Dermatology (Ghatge and Ghatge) reported improvements in hydration, firmness, brightness, texture and elasticity with HA alone, and generally good tolerability. However, most studies were not randomized, several had high risk of bias, endpoints were largely subjective, and no study reported long-term outcomes. The authors call for larger randomized trials.
What Safety Considerations Apply to Superficial Injectables?
Most reported events are mild and transient, but serious events, though rare, have been described, so training and preparedness matter.
In the Zhou and Yu analysis, most adverse events were redness, swelling, bumps and bruising. The review also noted individual serious cases, including one arterial ischemia event that resolved in 16 days. Ghatge and Ghatge likewise list bruising, swelling and tenderness as common and lumps, nodules or extrusion as rarer risks. Clinics should follow the manufacturer's instructions for use, maintain emergency protocols and have hyaluronidase available for HA products where appropriate. See our guide on HA filler vascular occlusion prevention and management.
Which Product Types Sit Under the Skin Booster Umbrella?
The category is broader than HA. Different molecules work through different mechanisms, and each carries its own labeling and documentation.
- Polynucleotide (PN) products: for example Rejuran Healer, Rejuran HB (PN plus HA) and Rejuran I for the periorbital area. Compare them in PN vs PDRN.
- Collagen-stimulating injectables: such as Olidia PLLA and Gouri liquid PCL, compared in PLLA vs PCL vs PDLLA.
- Combination formulations: such as LOMIERE (TXA, PDRN and HA) and Kiara Reju (PDRN with lidocaine).
- Structural HA fillers: such as Restylane (Galderma), used per its labeling for volume and contour.
Each product has its own intended use, injection technique and regulatory status. Always rely on the manufacturer's instructions for use rather than on category generalizations.
How Should Clinics and Distributors Choose Between Them?
Start with the clinical goal, then verify the product's labeling, documentation and handling requirements.
- Define the indication: volume loss and contour point to structural fillers; dull, dehydrated or fine-textured skin points to skin quality products, as determined by the practitioner.
- Match product to labeling: confirm intended use, depth and technique in the instructions for use.
- Verify authenticity and traceability: manufacturer, batch, expiry and packaging.
- Check regulatory fit: confirm what documents your destination market requires before importing.
- Plan storage and logistics: follow the manufacturer's storage conditions through shipping and in the clinic.
Frequently Asked Questions
Are skin boosters and dermal fillers the same thing?
No. Both can be built on hyaluronic acid, but fillers are designed mainly for volume and structure, while skin boosters are designed to improve dermal quality such as hydration and texture. Some products blur the line, and "skin booster" is not a formally standardized category, so always check each product's intended use and labeling.
Can a skin booster replace a filler?
Generally not. A skin booster is not intended to restore volume or contour, which is the role of firmer, more cross-linked gels. Practitioners often plan them as complementary treatments, with each product chosen for a different clinical goal, and the sequence and timing decided by the treating clinician.
Do skin boosters work, according to clinical evidence?
Evidence is encouraging but limited. A 2025 meta-analysis of injectable HA found improved hydration and radiance versus controls but no significant elasticity change, and it flagged few studies and high heterogeneity. A 2023 systematic review rated overall evidence quality as low. Outcomes vary between patients and products.
Are polynucleotide and PDRN products skin boosters too?
They are commonly grouped under the skin booster umbrella, although their mechanism is different from HA hydration. Polynucleotides are DNA-derived molecules, whereas HA is a glycosaminoglycan. Regulatory status and labeling differ by product and country, so distributors should verify documentation for each market.
What should distributors check before stocking skin boosters or fillers?
Verify the manufacturer, batch and expiry traceability, storage requirements, and the regulatory documents required in the destination country. Confirm the product's intended use matches how the clinic plans to use it, and ensure cold-chain and handling conditions follow the manufacturer's instructions.
Conclusion
Skin boosters and fillers answer different clinical questions, and a well-stocked clinic usually needs both categories, chosen with care. If you are a clinic, practitioner or distributor looking for certified Korean aesthetic products with documentation, contact HolyPath through our inquiry page to discuss your requirements.
References
- Zhou R, Yu M. The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta-Analysis. J Cosmet Dermatol. 2025;24(1):e16760. PMC11731322
- Ghatge AS, Ghatge SB. The Effectiveness of Injectable Hyaluronic Acid in the Improvement of the Facial Skin Quality: A Systematic Review. Clin Cosmet Investig Dermatol. 2023;16:891–899. PMC10082573
- de la Guardia C, et al. Rheologic and Physicochemical Characteristics of Hyaluronic Acid Fillers: Overview and Relationship to Product Performance. Facial Plast Surg. 2022;38(2):116–123. PMC9188840
- Yi K-H, et al. Skin boosters: Definitions and varied classifications. Skin Res Technol. 2024;30(3):e13627 (retracted 2025; cited only for terminology). PMC10938033
This article is for informational purposes for licensed medical professionals and distributors. It is not medical advice. Treatments should be performed only by qualified practitioners in accordance with local regulations.